Maridebart cafraglutide versus placebo for adults with obstructive sleep apnea on PAP therapy
Official title: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living With Overweight or Obesity
Run by Amgen · NCT07225686 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study will test whether maridebart cafraglutide helps adults with obstructive sleep apnea who use positive airway pressure therapy and are overweight or obese over 52 weeks.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Amgen Industry-sponsored |
| Locations | 51 sites (Northridge, California and 50 other locations) |
| Trial ID | NCT07225686 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with obstructive sleep apnea (AHI ≥ 15) who are overweight or obese (BMI ≥ 27), have previously tried and not sustained weight loss, and have been on PAP therapy for at least three months are ideal candidates.
✕Probably not a fit
Patients whose breathing disorder is primarily central apnea, those with significant craniofacial abnormalities, recent or planned upper airway surgery, active non‑PAP OSA treatments that cannot be stopped, or people who are not overweight are unlikely to receive benefit from this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 3 trial compares maridebart cafraglutide to a matching placebo over 52 weeks in adults with obstructive sleep apnea who are receiving positive airway pressure (PAP) therapy and have BMI ≥ 27. Eligible participants must have an apnea–hypopnea index (AHI) ≥ 15, a history of at least one unsuccessful weight-loss attempt, and have used PAP therapy for at least three consecutive months. Participants receive the study drug or placebo while continuing PAP therapy, and investigators monitor safety, body weight, and measures of sleep-disordered breathing. The trial is conducted at outpatient clinical research sites in the United States.
Why it matters
Potential benefit: If successful, maridebart cafraglutide could help people with obesity and OSA lose weight and reduce the severity of sleep apnea while continuing PAP therapy.
How similar studies have gone: Other GLP‑1–class weight-loss medications have produced substantial weight loss and shown improvements in sleep apnea measures in prior studies, though this specific compound is being evaluated separately in a Phase 3 program.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * AHI ≥ 15 on polysomnography at day 1 before randomization. * BMI ≥ 27 kg/m\^2 at screening. * History of at least 1 unsuccessful attempt at weight loss by diet and exercise. * On positive airway pressure (PAP) therapy for at least 3 consecutive months before screening and plan to continue PAP therapy during the trial. Exclusion Criteria: * Had any previous or planned upper airway surgery for sleep apnea or major ear, nose, or throat surgery. * Significant craniofacial abnormalities that may affect breathing at screening. * Diagnosis of Central Apnea with % of central apneas/hypopneas ≥ 50%, and/or diagnosis of Cheyne Stokes Respiration. * Active device treatment of obstructive sleep apnea other than PAP therapy (eg, oral appliances), or other treatments, that in the opinion of the investigator, may interfere with trial outcomes, unless willing to stop treatment at screening and throughout the trial. * Respiratory diseases such as obesity hypoventilation syndrome or daytime hypercapnia, or neuromuscular diseases such as myasthenia gravis or other conditions that could interfere with the results of the trial in the opinion of the investigator. * Have personal circumstances or job-related responsibilities that prevent a 7-day PAP withdrawal before polysomnography testing during the course of the trial.
Where it's running
-
Valley Clinical Trials
Northridge, California, United States Recruiting -
Peninsula Research Associates
Rolling Hills Estates, California, United States Recruiting -
Teradan Clinical Trials
Brandon, Florida, United States Recruiting -
Destiny Research Center
Palmetto Bay, Florida, United States Recruiting -
Clinical Research Center Of Florida
Pompano Beach, Florida, United States Recruiting -
NeuroTrials Research
Atlanta, Georgia, United States Recruiting
Show 44 more locations
-
Basil Clinical
Laurelton, New York, United States Recruiting -
Monroe Biomedical Research
Monroe, North Carolina, United States Recruiting -
CTI Clinical Research Center
Cincinnati, Ohio, United States Recruiting -
FutureSearch Trials of Neurology
Austin, Texas, United States Recruiting -
Epic Medical Research - DeSoto
DeSoto, Texas, United States Recruiting -
Sleep Therapy & Research Center
San Antonio, Texas, United States Recruiting -
Northwest Clinical Research Center
Bellevue, Washington, United States Recruiting -
Woolcock Institute of Medical Research
Macquarie Park, New South Wales, Australia Recruiting -
Royal Brisbane and Womens Hospital
Herston, Queensland, Australia Recruiting -
Monash Medical Centre
Clayton, Victoria, Australia Recruiting -
Nucleo de Pesquisa do Rio Grande do Sul
Porto Alegre, Rio Grande do Sul, Brazil Recruiting -
CPQuali Pesquisa Clinica Ltda
São Paulo, São Paulo, Brazil Recruiting -
Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo Hcfmusp
São Paulo, São Paulo, Brazil Recruiting -
CaRe Clinic
Calgary, Alberta, Canada Recruiting -
Aggarwal and Associates Ltd
Brampton, Ontario, Canada Recruiting -
Wharton Medical Clinic
Hamilton, Ontario, Canada Recruiting -
Nemocnice Rudolfa a Stefanie Benesov as
Benesov U Prahy, Czechia Recruiting -
Fakultni nemocnice Brno
Brno, Czechia Recruiting -
Cerebrovaskularni poradna sro
Ostrava - Poruba, Czechia Recruiting -
Centre Hospitalier Universitaire d'Angers
Angers, France Recruiting -
Centre Hospitalier Universitaire de Bordeaux - Hopital Pellegrin
Bordeaux, France Recruiting -
Centre Hospitalier Universitaire de Grenoble - Hopital Nord Michallon
Grenoble, France Recruiting -
Hospices Civils de Lyon - Centre Hospitalier Lyon Sud
Pierre-Bénite, France Recruiting -
Advanced Sleep Research
Berlin, Germany Recruiting -
InnoDiab Forschung
Essen, Germany Recruiting -
Diabeteszentrum Hamburg West
Hamburg, Germany Recruiting -
Siteworks - Zentrum fuer klinische Studien Hannover
Hanover, Germany Recruiting -
Siteworks - Zentrum fuer klinische Studien Karlsruhe
Karlsruhe, Germany Recruiting -
Red-Institut GmbH
Oldenburg, Germany Recruiting -
SomnoCenter Budapest Alvaszavar Kozpont
Budapest, Hungary Recruiting -
Debreceni Egyetem Klinikai Kozpont
Debrecen, Hungary Recruiting -
Erzsebet Gondozohaz
Gödöllő, Hungary Recruiting -
SomnoCenter Szeged Alvaszavar Kozpont
Szeged, Hungary Recruiting -
Reformatus Pulmonologiai Centrum
Törökbálint, Hungary Recruiting -
Saiseikai Futsukaichi Hospital
Chikushino-shi, Fukuoka, Japan Recruiting -
Fukuoka University Hospital
Fukuoka, Fukuoka, Japan Recruiting -
Sleep and Mental Clinic-Kitahiroshima
Kitahiroshima-shi, Hokkaido, Japan Recruiting -
Kuwamizu Hospital
Kumamoto, Kumamoto, Japan Recruiting -
Nakamura Clinic
Urasoe-shi, Okinawa, Japan Recruiting -
Gokeikai Osaka Kaisei Hospital
Osaka, Osaka, Japan Recruiting -
Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy
Warsaw, Poland Recruiting -
Centro Medico Teknon
Barcelona, Catalonia, Spain Recruiting -
Hospital Universitari Vall d Hebron
Barcelona, Catalonia, Spain Recruiting -
Hospital Medico Quirurgico San Rafael
A Coruña, Galicia, Spain Recruiting
+1 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: Amgen Call Center
- Email: medinfo@amgen.com
- Phone: 866-572-6436
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Lifestyle changes plus nightly CPAP for glaucoma in people with sleep apnea
This test checks whether adding a low-calorie diet and regular walking to nightly CPAP lowers eye pressure in people with high‑pressure open‑angle glaucoma who also have obstructive sleep apnea and obesity.
-
Evaluating body fat changes and sleep apnea resolution after bariatric surgery
This study is testing if losing body fat after bariatric surgery helps people with severe obesity and sleep apnea get better and possibly stop needing their CPAP machines.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Multimodal Deep Learning to Predict Sleep Apnea Severity from SpO2 and Ballistocardiography
Researchers are testing a smart-mattress-based method that uses SpO2 and ballistocardiography data to predict sleep apnea severity in adults undergoing overnight sleep study.
-
Nightly wearable monitoring with at-home submental electrical stimulation for sleep apnea
This pilot test checks whether wearing a ring sensor at night and doing a 4-week at-home submental electrical stimulation is feasible for adults with obstructive sleep apnea and looks at changes in sleep metrics.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.